Verastem, Inc. - Special Call Transcript
Good morning, and welcome to the Verastem Oncology Investor Conference Call on Monday, April 27, 2020. (Operator Instructions) Please be advised that this call is being recorded at the company's request and will be available on the company's website for a period of 90 days from today.
At this time, I would like to introduce Mr. John Doyle, Vice President of Investor Relations and Finance at Verastem Oncology. Please go ahead.
Welcome, everyone, and thank you for joining us this morning. With me today to discuss the preliminary clinical data from the ongoing Phase I combination study investigating VS-6766 and defactinib in KRAS mutant solid tumors are: Brian Stuglik, Chief Executive Officer; Dr. Jonathan Pachter, Chief Scientific Officer; Dr. Udai Banerji, Professor of Molecular Cancer Pharmacology at the Institute of Cancer Research, Honorary Consultant in Medical Oncology at the Royal Marsden NHS Foundation Trust and Lead Investigator of the clinical study; and Dan Paterson, President and Chief
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |